0      0

2020 Conference & Advanced Posters

P07_NonCE - Once-Daily Vibegron 75 mg for Overactive Bladder (OAB) Is Generally Safe and Well Tolerated, and Is Efficacious in Patients Aged ≥65 or ≥75 Years: EMPOWUR Randomized, International, Phase 3 Study


Purpose: For EMPOWUR, key efficacy endpoints are reported for patients with OAB aged ≥65 and ≥75 years, and overall.

Background/significance: Vibegron is a novel, once-daily, oral β3 agonist for OAB. In EMPOWUR, vibegron 75 mg showed statistically significant improvement in daily micturitions and urged urinary incontinence (UUI) episodes (p4% vibegron and >placebo) was headache (placebo, 2.2%; vibegron, 4.5%; tolterodine 2.3%).

Conclusions/implications: Treatment with vibegron for 12 weeks was generally safe and well tolerated, and was efficacious in all OAB patients, including those aged ≥65 and ≥75 years.

Funding: Urovant Sciences


  • Diane K. Newman, DNP, FAAN, BCB-PMD, Professor and Co-Director of the Penn Center for Continence and Pelvic Health, Perelman School of Medicine, University of Pennsylvania

You must be logged in and own this session in order to post comments.